Investors
2025 Annual Report and Responsible Business Report
Read about our strong performance and pipeline momentum in 2025.
Who we are
As a focused biopharma company, we discover, develop and deliver medicines and vaccines to create value for patients and shareholders. We aim to positively impact the health of 2.5 billion people by the end of the decade.Our R&D focus is on four therapeutic areas: respiratory, immunology and inflammation; oncology; HIV; and infectious diseases.

INVESTORS
We announced our full year and fourth quarter 2025 results on Wednesday 4 February















